What happened in China While European deeptech investors and founders have been closely watching Western brain-computer interface (BCI) pioneers conduct highly publicized clinical trials, a quiet but far more significant commercial milestone has just occurred in China. Neuracle's NEO-ONE SCI received its first prescription at Shanghai Huashan Hospital. This single event completed the world's first full commercial cycle of an invasive BCI device—spanning from approval to surgery to insurance coverage. This is a watershed moment for the global neurotech industry. It demonstrates that China has built a highly streamlined, end-to-end pipeline capable of moving invasive medical hardware from the lab to a reimbursed clinical reality at unprecedented speed. For European founders and investors, the lesson is clear: the real competitive threat from China is not just technological innovation, but the sheer velocity of its regulatory and commercialization ecosystem. ## How it works / the detail The commercial cycle completed…